MDxHealth S.A. (0O8G.L) LSE
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
MDxHealth S.A.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
312
First IPO Date
August 05, 2008
Key Executives
| Name | Title | Pay | Year Born |
| Michael K. McGarrity | Chief Executive Officer & Executive Director | 779,147 | 1963 |
| Joseph Sollee | Executive Vice President of Corporate Development & General Counsel | 0 | 1965 |
| John A. Bellano | Chief Commercial Officer | 0 | 1969 |
| Ron Kalfus | Interim Chief Financial Officer | 0 | 1974 |
| Scott McMahan | Vice President of Finance and Accounting | 0 | N/A |
| Kim Leroux | Executive Vice President of Revenue Cycle Management | 0 | N/A |
Description
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
